Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Photochromic blockers of voltage-gated potassium channels.

Banghart MR, Mourot A, Fortin DL, Yao JZ, Kramer RH, Trauner D.

Angew Chem Int Ed Engl. 2009;48(48):9097-101. doi: 10.1002/anie.200904504. No abstract available.

2.

Predictive models for hERG potassium channel blockers.

Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, Cruciani G, Vaz RJ.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3637-42.

PMID:
15978804
3.

Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.

Schmalhofer WA, Bao J, McManus OB, Green B, Matyskiela M, Wunderler D, Bugianesi RM, Felix JP, Hanner M, Linde-Arias AR, Ponte CG, Velasco L, Koo G, Staruch MJ, Miao S, Parsons WH, Rupprecht K, Slaughter RS, Kaczorowski GJ, Garcia ML.

Biochemistry. 2002 Jun 18;41(24):7781-94.

PMID:
12056910
4.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

Beshore DC, Liverton NJ, McIntyre CJ, Claiborne CF, Libby B, Culberson JC, Salata JJ, Regan CP, Lynch JJ, Kiss L, Spencer RH, Kane SA, White RB, Yeh S, Hartman GD, Dinsmore CJ.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. doi: 10.1016/j.bmcl.2010.03.005. Epub 2010 Mar 4.

PMID:
20304642
5.

Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.

Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS.

Mol Pharmacol. 2010 Oct;78(4):588-99. doi: 10.1124/mol.110.064014. Epub 2010 Jul 2.

6.

Cobatoxin 1 from Centruroides noxius scorpion venom: chemical synthesis, three-dimensional structure in solution, pharmacology and docking on K+ channels.

Jouirou B, Mosbah A, Visan V, Grissmer S, M'Barek S, Fajloun Z, Van Rietschoten J, Devaux C, Rochat H, Lippens G, El Ayeb M, De Waard M, Mabrouk K, Sabatier JM.

Biochem J. 2004 Jan 1;377(Pt 1):37-49.

7.

Structural basis for the inhibition of voltage-dependent K+ channel by gating modifier toxin.

Ozawa S, Kimura T, Nozaki T, Harada H, Shimada I, Osawa M.

Sci Rep. 2015 Sep 18;5:14226. doi: 10.1038/srep14226.

8.

Two dyad-free Shaker-type K⁺ channel blockers from scorpion venom.

Zhu L, Gao B, Luo L, Zhu S.

Toxicon. 2012 Mar 1;59(3):402-7. doi: 10.1016/j.toxicon.2011.11.016. Epub 2012 Jan 4.

PMID:
22239942
9.

Voltage-gated potassium+ channel expression in coronary artery smooth muscle cells of SHR and WKY.

Hu Z, Ma A, Zhang Y, Xi Y, Fan L, Wang T, Zhang T.

Cell Biochem Biophys. 2014 Dec;70(3):1725-31. doi: 10.1007/s12013-014-0120-4.

PMID:
25030407
10.

Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.

Liu H, Gao ZB, Yao Z, Zheng S, Li Y, Zhu W, Tan X, Luo X, Shen J, Chen K, Hu GY, Jiang H.

J Med Chem. 2007 Jan 11;50(1):83-93.

PMID:
17201412
11.

1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers.

Gordon E, Cohen JL, Engel R, Abbott GW.

Mol Pharmacol. 2006 Mar;69(3):718-26. Epub 2005 Nov 29.

12.

Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.

Peukert S, Brendel J, Pirard B, Brüggemann A, Below P, Kleemann HW, Hemmerle H, Schmidt W.

J Med Chem. 2003 Feb 13;46(4):486-98.

PMID:
12570371
13.

Electrophysiological characterization of a novel Kv channel blocker N,N'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl) ]bis(4-methyl)-benzenesulfonamide found in virtual screening.

Gao ZB, Chen XQ, Jiang HL, Liu H, Hu GY.

Acta Pharmacol Sin. 2008 Apr;29(4):405-12. doi: 10.1111/j.1745-7254.2008.00777.x.

14.

Enhancement of voltage-gated K+ channels and depression of voltage-gated Ca2+ channels are involved in quercetin-induced vasorelaxation in rat coronary artery.

Hou X, Liu Y, Niu L, Cui L, Zhang M.

Planta Med. 2014 Apr;80(6):465-72. doi: 10.1055/s-0034-1368320. Epub 2014 Apr 7.

PMID:
24710898
15.

Potent Kv1.3 inhibitors from correolide-modification of the C18 position.

Bao J, Miao S, Kayser F, Kotliar AJ, Baker RK, Doss GA, Felix JP, Bugianesi RM, Slaughter RS, Kaczorowski GJ, Garcia ML, Ha SN, Castonguay L, Koo GC, Shah K, Springer MS, Staruch MJ, Parsons WH, Rupprecht KM.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.

PMID:
15603971
16.

[Influence of 4-aminopyridine on cell proliferation through inhibiting voltage-gated K+ channel in ovarian cancer].

Weng ZP, Wang B, Wang SL, Cui N, Pan XY.

Zhonghua Fu Chan Ke Za Zhi. 2006 Nov;41(11):762-5. Chinese.

PMID:
17327035
17.

A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties.

Peigneur S, Billen B, Derua R, Waelkens E, Debaveye S, Béress L, Tytgat J.

Biochem Pharmacol. 2011 Jul 1;82(1):81-90. doi: 10.1016/j.bcp.2011.03.023. Epub 2011 Apr 6.

PMID:
21477583
18.

A quantitative structure-activity relationship study on some series of potassium channel blockers.

Satuluri VS, Seelam J, Gupta SP.

Med Chem. 2009 Jan;5(1):87-92.

PMID:
19149654
19.

Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers.

Lloyd J, Schmidt JB, Rovnyak G, Ahmad S, Atwal KS, Bisaha SN, Doweyko LM, Stein PD, Traeger SC, Mathur A, Conder ML, DiMarco J, Harper TW, Jenkins-West T, Levesque PC, Normandin DE, Russell AD, Serafino RP, Smith MA, Lodge NJ.

J Med Chem. 2001 Nov 8;44(23):3764-7.

PMID:
11689063
20.

A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.

Harvey AJ, Gable RW, Baell JB.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3193-6.

PMID:
15935664

Supplemental Content

Support Center